Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Strong

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Surgical Endoscopy|June 27, 2025
Long-term outcomes of laparoscopic duodenojejunostomy for superior mesenteric artery syndromeMélissa V Wills, Juan S Barajas-Gamboa, Valentin Mocanu, et al.
Ophthalmology|November 4, 2004
Verteporfin in Photodynamic Therapy: report no. 5Francesco Bandello, Kevin Blinder, Neil M Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 10, 2003
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2Irene Barbazetto, Amy Burdan, Neil M Bressler, et al.
Ophthalmology|February 27, 2009
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degenerationPeter K Kaiser, , David S Boyer, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|March 6, 2003
Improvement after verteporfin therapyRajiv Anand, Neil M Bressler, Susan B Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 21, 2002
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3Neil M Bressler, Jennifer Arnold, Mustapha Benchaboune, et al.
American Journal of Ophthalmology|September 12, 2003
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1Keven J Blinder, Shannon Bradley, Neil M Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 15, 2005
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7Neil M Bressler, Susan B Bressler, Laurie A Haynes, et al.
American Journal of Ophthalmology|April 3, 2004
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3Jennifer J Arnold, Kevin J Blinder, Neil M Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 13, 2005
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trialMohammad Azab, David S Boyer, Neil M Bressler, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Surgical Endoscopy|June 27, 2025
Long-term outcomes of laparoscopic duodenojejunostomy for superior mesenteric artery syndromeMélissa V Wills, Juan S Barajas-Gamboa, Valentin Mocanu, et al.
Ophthalmology|November 4, 2004
Verteporfin in Photodynamic Therapy: report no. 5Francesco Bandello, Kevin Blinder, Neil M Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 10, 2003
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2Irene Barbazetto, Amy Burdan, Neil M Bressler, et al.
Ophthalmology|February 27, 2009
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degenerationPeter K Kaiser, , David S Boyer, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|March 6, 2003
Improvement after verteporfin therapyRajiv Anand, Neil M Bressler, Susan B Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 21, 2002
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3Neil M Bressler, Jennifer Arnold, Mustapha Benchaboune, et al.
American Journal of Ophthalmology|September 12, 2003
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1Keven J Blinder, Shannon Bradley, Neil M Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 15, 2005
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7Neil M Bressler, Susan B Bressler, Laurie A Haynes, et al.
American Journal of Ophthalmology|April 3, 2004
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3Jennifer J Arnold, Kevin J Blinder, Neil M Bressler, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 13, 2005
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trialMohammad Azab, David S Boyer, Neil M Bressler, et al.
Pageof 7